1350653-20-1
- Product Name：Vericiguat
- Molecular Formula：C19H16F2N8O2
- Purity：99%
- Molecular Weight：426.385
Product Details:
CasNo： 1350653-20-1
Molecular Formula： C19H16F2N8O2
Appearance： Light yellow to yellow solid
Chinese Manufacturer Supply Vericiguat,Sale 1350653-20-1 Efficient Transportation
- Molecular Formula:C19H16F2N8O2
- Molecular Weight:426.385
- Appearance/Colour:Light yellow to yellow solid
- Boiling Point:535.9±50.0 °C(Predicted)
- PKA:10.61±0.70(Predicted)
- PSA：151.08000
- Density:1.63±0.1 g/cm3(Predicted)
- LogP:3.08240
Vericiguat(Cas 1350653-20-1) Usage and Manufacturer
|
Description |
Vericiguat is a medication classified as a soluble guanylate cyclase (sGC) stimulator. It acts by enhancing the activity of the enzyme sGC, which catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). This leads to vasodilation and other beneficial effects in the cardiovascular system. Hangzhou Huarong Pharm Co., Ltd., founded in 2009, is dedicated to providing innovative products and services for small molecule drug discovery and development. The company specializes in research, development, and manufacturing across a range of fields, including Building Blocks, Reference Compounds & Impurities, Natural Products, APIs & Intermediates, and Antibody-drug Conjugates (ADCs). With a focus on R&D, Huarong Pharm has invested heavily in state-of-the-art facilities and GMP-certified plants. It has successfully served over 3,000 partners globally and aims to become a world leader in supporting life science innovation. The company’s core values are responsibility, teamwork, professionalism, efficiency, and continuous growth. |
|
Uses |
Vericiguat is primarily indicated for the treatment of heart failure with reduced ejection fraction (HFrEF). It is prescribed to certain adults who have experienced recent hospitalization for heart failure or who have received intravenous diuretic therapy. Vericiguat aims to reduce the risk of death and the need for hospitalization in these patients by improving cardiac function and alleviating symptoms associated with heart failure. |
1350653-20-1 Relevant articles
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong, M.D., Burkert Pieske, M.D., Kevin J. Anstrom, Ph.D., Justin Ezekowitz, M.B., B.Ch., Adrian F. Hernandez, M.D., M.H.S., Javed Butler, M.D., M.P.H., M.B.A., Carolyn S.P. Lam, M.B., B.S., Ph.D.,
The New England Journal of Medicine, VOL. 382 NO. 20
The composite of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1032 patients (40.9%) in the placebo group (hazard ratio, 0.90; 95% CI, 0.83 to 0.98; P=0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (P=0.12), and syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (P=0.30).
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure
Follmann, Markus,Ackerstaff, Jens,Redlich, Gorden,Wunder, Frank,Lang, Dieter,Kern, Armin,Fey, Peter,Griebenow, Nils,Kroh, Walter,Becker-Pelster, Eva-Maria,Kretschmer, Axel,Geiss, Volker,Li, Volkhart,Straub, Alexander,Mittendorf, Joachim,Jautelat, Rolf,Schirok, Hartmut,Schlemmer, Karl-Heinz,Lustig, Klemens,Gerisch, Michael,Knorr, Andreas,Tinel, Hanna,Mondritzki, Thomas,Trübel, Hubert,Sandner, Peter,Stasch, Johannes-Peter
, p. 5146 - 5161 (2017/06/28)
The first-in-class soluble guanylate cyc...
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
List of authors. Paul W. Armstrong, M.D., Burkert Pieske, M.D., Kevin J. Anstrom, Ph.D., Justin Ezekowitz, M.B., B.Ch., Adrian F. Hernandez, M.D., M.H.S., Javed Butler, M.D., M.P.H., M.B.A., Carolyn S.P. Lam, M.B., B.S., Ph.D., Piotr Ponikowski, M.D., Adriaan A. Voors, M.D., Ph.D., Gang Jia, Ph.D., Steven E. McNulty, M.S., Mahesh J. Patel, M.D
N Engl J Med 2020; 382:1883-1893
In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose, 10 mg once daily) or placebo, in addition to guideline-based medical therapy.
USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES
-
Paragraph 0156-0161, (2013/06/28)
The present invention relates to the nov...
1350653-20-1 Upstream products
-
113237-20-0
2,6-dichloro-5-fluoropyridine-3-carboxamide
-
1350653-30-3
2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine
-
79-22-1
methyl chloroformate
-
82671-02-1
2,6-dichloro-5-fluoro-pyridine-3-carbonitrile
1350653-20-1 Downstream products
-
1350653-21-2
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate
-
1350653-22-3
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate
-
1350659-01-6
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate maleate
-
1350658-99-9
methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate mesylate
Relevant Products
-
PralsetinibCAS：2097132-94-8
-
AzacitidineCAS：320-67-2
-
UbrogepantCAS：1374248-77-7
